Pneumologie 2025; 79(S 01): S30-S31
DOI: 10.1055/s-0045-1804601
Abstracts
A3 – Interstitielle und seltene Lungenkrankheiten

Effect of Admilparant (BMS-986278), an oral LPA1 antagonist, on time to disease progression in patients with pulmonary fibrosis: a post hoc analysis of a randomized trial

M Kreuter
1   Mainz Center for Pulmonary Medicine, Departments of Pneumology, Mainz University Medical Center of Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz
,
T Maher
2   University of Southern California; University of Southern California
,
W Wuyts
3   University Hospitals Leuven; Department of Respiratory Medicine
,
C Valenzuela
4   Ild Unit, Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autonoma de Madrid
,
M Hamblin
5   University of Kansas Medical Center; Pulmonary and Critical Care Medicine
,
S Kim
6   Bristol Myers Squibb
,
A Patel
6   Bristol Myers Squibb
,
B Elpers
6   Bristol Myers Squibb
,
L Richeldi
7   Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica del Sacro Cuore
› Author Affiliations
 
 

    Background: Admilparant (BMS-986278) is an investigational lysophosphatidic acid receptor 1 antagonist to treat idiopathic and progressive pulmonary fibrosis (IPF/PPF). The effect vs placebo (pbo) on time to disease progression (TTP) was analyzed post-hoc in a phase 2 trial (NCT04308681).

    Methods: Two cohorts of patients (pts), IPF or PPF, were randomized to receive 26 weeks 30mg, 60mg Admilparant or pbo BID; antifibrotic background therapy was allowed. Disease progression was a composite of relative percent predicted forced vital capacity (ppFVC) decline≥10%, acute exacerbation, all-cause hospitalization, and all-cause mortality. Subgroup analyses were based on median ppFVC at baseline (BL). A Kaplan-Meier product-limit approach assessed time to first event over 26 weeks.

    Results: 255 IPF and 114 PPF pts were included. Median ppFVC at baseline was 77.25% in the IPF and 64.70% in the PPF cohort. Treatment with 60mg delayed TTP over 26 weeks compared with pbo ([Fig. 1]). A similar trend was observed in the subgroup analysis of pts with BL ppFVC below or above median.

    Conclusions: Results support further evaluation of Admilparant as option for IPF and PPF pts.

    Zoom Image
    Fig. 1  Time to disease progression in patients with IPF (A) and PPF (B) Hazard ratios (HRs) were estimated using a Cox proportional hazard model.

    Keywords: clinical trial; lysophosphatidic acid receptor 1 antagonist; idiopathic pulmonary fibrosis; progressive pulmonary fibrosis; admilparant


    #

    Publication History

    Article published online:
    18 March 2025

    © 2025. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

     
    Zoom Image
    Fig. 1  Time to disease progression in patients with IPF (A) and PPF (B) Hazard ratios (HRs) were estimated using a Cox proportional hazard model.